Clinical Data, Inc. (NASDAQ: CLDA) today announced the election of Scott Tarriff to the Board of Directors. Mr. Tarriff has 25 years of pharmaceutical experience, including serving as President and Chief Executive Officer of Par Pharmaceutical, Inc., where he established the company`s first branded pharmaceutical division, and a 12-year career with Bristol-Meyers Squibb.
"Scott brings relevant pharmaceutical business and operational expertise to Clinical Data," said Drew Fromkin, Clinical Data`s President and Chief Executive Officer. "In addition, his experience leading the successful introduction of a number of therapeutic products will be an asset to the Company as we plan for commercialization of our own late-stage product candidates."
In January 2007, Mr. Tarriff formed Eagle Pharmaceuticals, Inc., a hospital specialty company focused on developing, distributing and in-licensing injectable IV products. Prior to forming Eagle, Mr. Tarriff was President and Chief Executive Officer of Par Pharmaceutical Companies, Inc. He joined Par Pharmaceutical Companies, Inc. as Executive Vice President of Business in 1998 and was named President and Chief Executive Officer of Par Pharmaceutical, Inc., the company`s principal operating subsidiary, in 2001. Mr. Tarriff was elected to its Board of Directors in 2002 and appointed President and Chief Executive Officer of Par Pharmaceutical Companies, Inc. in September 2003.
Under Mr. Tarriff`s direction, Par achieved growth through an aggressive global business development program. He strengthened manufacturing and substantially increased investment in research and development. Before founding his own company, Eagle Pharmaceuticals, Inc., Mr. Tarriff led the most successful product introductions in Par`s history, including generic versions of Prozac®, Paxil®, Megace® O/S, Ultracet® and the company`s first branded pharmaceutical product, Megace® ES.
"This is an ideal time for me to join the Board of Clinical Data as the Company expands its presence in the pharmaceutical market and continues to advance the development of a distinguished product pipeline," said Mr. Tarriff. "I look forward to working closely with the Board to help guide Clinical Data`s further transition to a commercial-stage pharmaceutical company."
Mr. Tarriff joined Par following over a decade with Bristol-Meyers Squibb. He received his MBA from Rider College and his undergraduate degree from Pennsylvania State University.
Mr. Tarriff`s appointment brings the number of directors on the Clinical Data Board to seven.
No comments:
Post a Comment